[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367890-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367890-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","problems-in-cancer-genome-medicine-base-mutations-cause-intron-start-signals-resulting-in-unexpected-splicing","Problems in Cancer Genome Medicine - Base Mutations Cause Intron Start Signals, Resulting in Unexpected Splicing","","Genetic features of surgically removed cancer tissues are analyzed using cancer gene panel testing in cancer genome medicine to identify pathogenic variants driving proliferation and progression. When an antitumor drug targets the detected pathogenic variant, careful professional consideration is still required. Mutation patterns differ by race, and VUS may contribute to onset or progression, supported by ClinVar results. Single nucleotide variations can produce silent mutations or create splice-site changes. Methods reexamine CGP VUS.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/problems-in-cancer-genome-medicine-base-mutations-cause-intron-start-signals-resulting-in-unexpected-splicing/367890/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/problems-in-cancer-genome-medicine-base-mutations-cause-intron-start-signals-resulting-in-unexpected-splicing/367890.png","ImageObject",300,407,{"name":42,"@type":43},"Bulrr","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why can cancer gene panel test–based diagnoses be incorrect?","Question",{"text":63,"@type":64},"The article concludes that diagnosing gene mutations from cancer gene panel results may not always be correct, because variants classified as VUS can still affect crucial processes like splicing. Therefore, detailed mutation examination is necessary.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study reexamine CGP results for suspected hereditary tumor cases?",{"text":68,"@type":64},"The study reexamined CGP VUS results in patients suspected of hereditary tumors using family background information, with IGV and RT-PCR to validate splicing effects.",{"name":70,"@type":61,"acceptedAnswer":71},"What splicing-related outcomes were observed in the reported VUS examples?",{"text":72,"@type":64},"KRAS Q61K was identified as a VUS by ClinVar but was found to cause splicing. SDHB G642T shifted the splicing site, preventing correct SDHB mRNA translation, and BRCA2 631 3A>T could create a splicing site so the correct BRCA2 mRNA was not produced.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367890,1791101109,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":106,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Original Article World J Oncol. 2025;16(5):471-477  \nProblems in Cancer Genome Medicine: Base Mutations Cause Intron Start Signals, Resulting in Unexpected Splicing  \nTakuma Hayashia, c, Ikuo Konishia, b  \nAbstract  \nBackground: The genetic characteristics of surgically removed cancerous tissues are examined using cancer gene panel testing in cancer genome medicine to detect the pathogenic variants involved in the proliferation and progression of cancer cells. An antitumor drug is prescribed if it directly acts on the detected pathogenic variant; however, some aspects require careful consideration by medical professionals in such cases. The genetic mutations involved in the progression or onset of malignant tumors differ with race. Furthermore, genetic mutations that are variants of unknown significance (VUS) may be involved in the progression or onset of malignant tumors in some races according to the ClinVar results from the National Center for Biotechnology Information. Single nucleotide variations can result in silent mutations or splice sites.  \nMethods: We therefore reexamined the CGP results (VUS) of patients suspected of developing hereditary tumors based on their family background using IGV and RT-PCR.  \nResults: KRAS Q61K, which is found in many gastrointestinal cancers, was identified as a VUS by ClinVar, but this gene mutation was found to cause splicing. The cancer gene panel test of a 41-year-old male patient with paraganglioma identified succinate dehydrogenase complex, iron-sulfur subunit B (SDHB) G642T as a VUS. However, this mutation was later discovered to cause the splicing site to shift, preventing SDHB from translating from the correct mRNA. In addition, a cancer gene panel test of a 47-year-old patient with right breast cancer determined that breast cancer susceptibility gene 2 (BRCA2) 631 3A>T was a VUS. However, this mutation may create a splicing site, which means that the correct BRCA2 mRNA for BRCA2 is not produced.  \nManuscript submitted June 24, 2025, accepted August 14, 2025  \nPublished online September 17, 2025  \naCancer Medicine, National Hospital Organization Kyoto Medical Center, Kyoto-city, Kyoto 612-8555, Japan  \nbDepartment of Obstetrics and Gynecology, Kyoto University Hospital, Kyoto-city, Kyoto 606-8507, Japan  \ncCorresponding Author: Takuma Hayashi, Cancer Medicine, National Hospital Organization Kyoto Medical Center, Mukaihatake-cho 1-1, Fukakusa, Fushimi-ku, Kyoto-city, Kyoto 612-8555, Japan.  \n[Email: yoyoyo224@hotmail.com](Email: yoyoyo224@hotmail.com)  \ndoi: [https://doi.org/10.14740/wjon2631](https://doi.org/10.14740/wjon2631)  \nConclusions: The diagnosis of gene mutations based on the results of cancer gene panel testing may not always be correct, and a detailed examination of gene mutations is necessary. Our medical staff has performed cancer gene panel testing on approximately 5,500 cases of intractable malignant tumors to date and are investigating new treatments for these tumors. In this article, we discuss our experience with cancer gene panel testing as well as the problems encountered and new findings.  \nKeywords: Cancer gene panel; Pathogenic variant; VUS; Splicing  \nIntroduction  \nCancer treatment has involved the selection of antitumor drugs according to the cancer type in each organ. The effectiveness of antitumor drugs against various cancer types has been examined, and antitumor drugs have been prescribed according to the treatment guidelines for each cancer type [1] . However, the effectiveness of antitumor drugs, as defined by clinical practice guidelines, is not always known. Cancer cells are heterogeneous, and the unique characteristics of each individual cancer cell strongly affect the efficacy of the prescribed antitumor agent [2] . The “Precision Medicine Initiative” was announced in 2015 in the USA, which is developing into a new cancer treatment known as cancer genome medicine, which isnot limited by the cancer type in each tissue [3, 4] .  \nFoundationOne® ","cbCaiqPDZDO7jk2t","https://ap.wps.com/l/cbCaiqPDZDO7jk2t","pdf",1125591,"English","# Introduction\n## Cancer genome medicine and drug selection\n## Cancer gene panel testing in Japan\n# Methods\n## CGP reexamination using IGV and RT-PCR\n# Results\n## KRAS Q61K causing splicing\n## SDHB G642T shifting the splicing site\n## BRCA2 631 3A>T creating a splicing site\n# Conclusions\n## Limits of panel-based mutation diagnosis\n## Need for detailed mutation examination","[{\"question\":\"Why can cancer gene panel test–based diagnoses be incorrect?\",\"answer\":\"The article concludes that diagnosing gene mutations from cancer gene panel results may not always be correct, because variants classified as VUS can still affect crucial processes like splicing. Therefore, detailed mutation examination is necessary.\"},{\"question\":\"How did the study reexamine CGP results for suspected hereditary tumor cases?\",\"answer\":\"The study reexamined CGP VUS results in patients suspected of hereditary tumors using family background information, with IGV and RT-PCR to validate splicing effects.\"},{\"question\":\"What splicing-related outcomes were observed in the reported VUS examples?\",\"answer\":\"KRAS Q61K was identified as a VUS by ClinVar but was found to cause splicing. SDHB G642T shifted the splicing site, preventing correct SDHB mRNA translation, and BRCA2 631 3A\\u003eT could create a splicing site so the correct BRCA2 mRNA was not produced.\"}]","Problems in Cancer Genome Medicine - Base Mutations Cause Intron Start Signals, Resulting in Unexpected Splicing | PDF",1790173176,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b5c5251070bf3d1967953bfd28f58c8.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6597c6cbaad9e3a46ee1ed37649f820.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70144520b0151863d8460ed49d505087.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19b299cbd67df1d612d2f25df7240c7a.webp",980,1268]